Vitroscope, a Norwegian biotech company, has raised US$7 million in new funding. It builds automated systems that keep living tissue alive and active for longer experiments. Cerberus Ventures and YZR Capital co-led a US$5 million Seed round, and the Research Council of Norway added US$2 million in non-dilutive funding.
Funding breakdown
The Seed round also drew participation from Arcas Ventures, Golden Egg Check, and Devico Invest. Angel investors including Carles Reina, Fàtima Godall, and Oskari Pétas joined the round. Vitroscope has raised US$8.8 million to date.
Company context
Vitroscope is based in Trondheim, Norway, and its CEO Carlo Kriesi is a co-founder. The company works with researchers using organoids and fresh human tissue. Tests have involved human brain organoids, liver cells, and kidney cells.
What the platform does
The vitro.alive system combines programmable perfusion with control of oxygen, pH, and temperature. It supports six independent experiments and works with standard inverted microscopes. A future platform, vitro.scale, will support 96 parallel experiments.
The new funding will support commercial rollout of vitro.alive and validation of vitro.scale. Customer testing for vitro.scale is expected to begin in 2027. The company plans to launch the higher-throughput platform in 2028.